• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA Advises Using COVID-19 Approaches to Support Ukrainian Clinical Trials

EMA Advises Using COVID-19 Approaches to Support Ukrainian Clinical Trials

April 4, 2022

As the Russia-Ukraine war rages, the European Medicines Agency (EMA) has openly addressed the crisis’ disruptions to trials in the Ukraine, calling on sponsors to implement COVID-19 flexibilities and approaches where and when they can.

The agency’s initial advice to sponsors running trials in the war-torn country is to take the lessons learned from the pandemic and apply them to trials that are currently being affected. Specifically, sponsors should refer to the EMA’s guidance on managing trials during the pandemic and guidance on the pandemic’s implications for methodological aspects of trials in progress.

“Certain changes and protocol deviations in the current situation are unavoidable, when for example scheduled study visits cannot take place or arrangements need to be made to transfer trial participants who are fleeing Ukraine to other investigator sites of the same trial in the European Union,” the EMA said. “Adaptations will also be needed to protect the participants’ right and safety, including the continuation of ongoing trial treatment if possible, as well as to preserve the quality of the data generated by the trials.”

The EMA’s recommendations come in response to sponsor inquiries on how trial records, documentation, data collection, protocol deviations and missing data should be handled in light of the war and its disruptions.

A guidance on managing trials during the pandemic includes recommendations for starting new trials; making changes to ongoing trials; maintaining safety reporting; performing risk assessments; communicating with authorities; and other topics.

A guidance on methodological implications advises sponsors not to stop collecting data if at all possible, to perform a risk assessment on potential impact to trial integrity/interpretability and to plan, in advance, how protocol deviations will be captured, among other critical things to consider.

Additional recommendations are being worked on by a group of clinical trial experts, while the EMA is in the process of developing further recommendations on methodological considerations for data coming from Ukrainian trials.

Read the guidance on managing trials during the pandemic here: https://bit.ly/3tWg7UE.

Read the guidance on methodological implications here: https://bit.ly/376dQgk.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing